April 25 - Day Two
Location: Room 3103/ 3104
This session will showcase the benefits, opportunities, and financing available in the APAC region and the most effective way of leading their respective business deals. Leading investors will share their insights on their success in investing across borders, where the focus is shifting in the next decade, the rising appeal of business in Asia, and the global impact.
- Min Wu - CBO, SciClone Pharmaceuticals
- Vince Deng - Partner, Med-Fine Capital
- Navjeewan Khosla - Partner, Novo Holdings
- Yuwen Liu - Founding Partner, Bohe Angel Fund
- Jing Xu - Investment Principal, LYFE Capital
Location: Room 3103/ 3104
So far 2024 has shown a promising start for IPOs, but is it sustainable? This session will cover opportunities and obstacles of recent biotech IPOs, reversing the previous downward trend, new and emerging ways to raise funds, what strategies can be implemented long-term, and how these pivots will affect product development.
- Yiming Liu - Partner, Cooley
- Ghee Chuan Lai - Associate, Qiming Venture Partners
- Vishal Doshi - Chairman of the Board, AUM Biosciences
- James Huang - Founder and Managing Partner, Panacea Venture
Location: Room 3103/ 3104
Building a competitive landscape and create a booming biopharma ecosystem requires support across borders. Global leaders in life sciences will share their experience with business, investment, and regulations while working in Asia, and how they have been able to meet or surpass expectations.
- Brian Yang - Managing Editor, Citeline
- Taejoon Chin - CEO, C Cube Lab
- Charles Stacey - President and CEO, Cerecin
- Nils Schrader - Managing Director, BIO.NRW
- PC Zhu - Founder and CEO, ATLATL
Location: Room 3103/ 3104
Hear from the latest AI innovators and supporters as they share ever-expanding capabilities and influence in AI-aided drug discovery and development, and the industry trends that will help facilitate the path forward.
- Tam C. Nguyen - Deputy Director of Research IC, Horizon 3 Healthcare, St Vincent’s Hospital Melbourne
- Anand Gautam - Founder, G2OME CONSULTING PTY LTD
- Frank Grams - CCO, Partex NV
- Yam Guan - Director, Oracle Health
- Jimmy Lin - General Manager, Insilico Medicine Taiwan
Location: Room 3103/ 3104
New for Asia Bio Partnering Forum, we are excited to launch the startup spotlight pitch competition. This high-energy session will feature some of the most innovative startup biotech companies entering the market today. The live pitch competition will give a group of hand selected startups the opportunity to pitch in front of the Asia Bio Partnering Forum judges and audience, with the winner announced at the end of the session.
Participating Companies:
Ananda Immunotherapies
Biorevert Inc
Fermelanta, Inc.
Elix, Inc.
Medicovestor, Inc.
VRG Therapeutics
- Tam C. Nguyen - Deputy Director of Research IC, Horizon 3 Healthcare, St Vincent’s Hospital Melbourne
- Ryan Wang - Head of Lilly Innovation Center, Eli Lilly
- Min Wu - CBO, SciClone Pharmaceuticals
- Adrian Lim - CEO, Ananda Immunotherapies
- Sea Choi - Co-Founder and Chief Global Strategist, Biorevert Inc
- Shogo Fukizaki - Co-Founder & CEO, Fermelanta, Inc.
- Shinya Yuki - CEO & Co-Founder, Elix, Inc.
- Lin Ong - CBO, Medicovestor, Inc.
- Zalán Péterfi - CEO & Co-Founder, VRG Therapeutics
Location: Room 3102
Adepthera is a preclinical-stage company dedicated to advancing long-acting peptide therapeutics through its leading scientific work on self-assembling slow-release peptides for GPCR targets. Adepthera's vision is to improve patients' lives with highly innovative therapies. Adpethera is dedicated to filling this gap by developing precise and efficient treatments using unique self-assembled peptide analogs.
Innovative peptide solutions are at the core of what we are developing at Adepthera. Our innovative approach integrates foundational science with innovative analogs to deliver new classes of peptide therapeutics for patients who suffer chronic pain, chronic wounds, or endothelial dysfunction. We have developed the first CGRP antagonist suitable for intra-articular delivery to alleviate joint pain and the first CLR/RAMP receptor agonist ideal for augmenting localized healing of chronic wounds. These self-assembled therapeutic candidates are currently in the IND-enabling stage of development. They are indicated for the prevention/mitigation of osteoarthritis pain and chronic migraine headaches in patients who are resistant to available therapies or for accelerating the healing of diabetic ulcers and pressure ulcers. In addition, select self-assembling candidates are indicated for the treatment of life-threatening cardiovascular diseases (e.g., stroke, preeclampsia, and resistant hypertension) resulting from endothelial dysfunction and the loss of vascular integrity. With these novel assets, our team of experienced drug developers is working to launch a new world of innovative peptidomimetic drugs.
Location: Room 3102
Genome Opinion is at the forefront of precision medicine development targeting diseases driven by Clonal Hematopoiesis (CH). Utilizing our proprietary GENO-VERSE database, we employ a strategic methodology to enhance our research and development efforts.
Our methodology encompasses:•Identifying specific patient demographics for targeted therapeutic interventions.•Discovering or acquiring tailored treatments for these groups.•Expediting the clinical trial process via early local POC studies.